Comparison of the Efficacy and Survival Analysis of Neoadjuvant Chemotherapy for Her-2-Positive Breast Cancer

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s171534
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Neoadjuvant Chemotherapy in Breast Cancer

English

Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer

Tumors of female reproductive system
2017English

Clinical Experience of Dual Targeted Blockade (Pertuzumab + Trastuzumab + Docetaxel) in Neoadjuvant Therapy of Early HER-2-Positive Breast Cancer

Effective Pharmacotherapy
2019English

Efficacy of Single Cycle Neoadjuvant Chemotherapy in Carcinoma Breast

International Journal of Surgery Science
2019English

Neoadjuvant Chemotherapy: Role in Breast Cancer

2013English

Neoadjuvant Chemotherapy of Capecitabine + Epirubicin + Cyclophosphamide Combination Therapy ( 'CEX' Therapy) for HER-2 Negative Breast Cancer, as Retrospective Study in Our Institute

Journal of Nippon Medical School
Medicine
2019English

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine
Medicine
2012English

Neoadjuvant Chemotherapy for Early Breast Cancer – Author's Reply

The Lancet Oncology
Oncology
2018English

Lapatinib Plus Capecitabine in Women With HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

Oncologist
Cancer ResearchMedicineOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy